Services

Evidence, Access & Pricing

Our team of experts work across functions to develop locally nuanced and comprehensively global strategies spanning evidence, value, access and pricing.

Home / Services / Evidence, Access & Pricing

The pharma-biotech landscape is rapidly evolving, creating a range of challenges for manufacturers who need to generate evidence, communicate value, and optimize their products’ pricing and access. 

Trinity’s Evidence, Value, Access and Pricing team team has unparalleled experience across geographies and therapeutic areas. We work across the product lifecycle, addressing needs at a global & local level. 

The Trinity Difference: 

  • An integrated approach across all offerings and areas of Evidence, Value, Access, and Pricing expertise 
  • In-depth therapeutic area and product modality experience, including cell and gene therapies  
  • Scientifically rigorous methodologies and real-world studies to drive impactful evidence and publications 
  • Compelling real-world data analytics and modeling expertise 
  • Deep market access expertise, leveraging extensive knowledge of access trends / policy changes  
  • Global list and net pricing methodological expertise, including in-depth U.S. payer / provider contracting 
  • First-hand negotiation experience translated into both our strategies and our negotiation training program 

Products 

We have supported the evidence, value, access & pricing strategy of the majority of innovative launches over the last decade, and have experience spanning across most therapeutic areas.

Experts

Our team consists of experts with in-depth local knowledge and native language skills that contribute towards the development of Trinity’s Geo-Knowledge Resource Hubs which span across all major geographies. 

Network

We have an extensive in-house payer network, and access to key stakeholders ranging from national government authorities to local hospital and practice administrators / executives. 

Impact

We have a vast portfolio of successful evidence generation and value demonstration studies which have translated into access and commercial success. 

Geo-Knowledge Resource Hubs

Trinity’s Geo-Knowledge Resource Hubs distill deep market knowledge, cultivate best practices, and generate thought leadership. 

  • USA

    Trinity has extensive experience across differential payer stakeholders in the US – MCOs, PBMs, MACs, Practice Managers, Pathway Vendors, etc. With a constantly evolving pricing and access landscape, we must always have a pulse on the changing policy landscape and be ready to pivot our strategies accordingly. We work with clients across the product lifecycle starting with early phase “gut checks” to thorough price analyses and contracting strategies to ensure an optimized launch.

    Questions Our Clients Ask
    • How restrictive will the payer prior authorization be for our product?
    • What is our value-based price?
    • How will access change for the follow-on indication?
    • What will payer management look like in disease state X in the next five years?
    • What are the specific access hurdles the practice is experiencing with our product?
    Specialized Markets

    USA

    The Trinity Difference
    • We have vast experience supporting the pricing and access launch strategy of high-profile brands and can help clients solve highly nuanced problems (i.e. HUB financial assistance program, differential pricing across indications, DRG-based reimbursement and NTAP considerations, etc.)
    • We have extensive experience with high profile dynamics such as: cell and gene therapy, alternative payment models, NGS testing, and portfolio contracting
  • Asia Pacific

    Trinity’s expertise spans many different healthcare systems and payer landscapes within the Asia Pacific region. We have a deep knowledge of the nuanced differences within each market of the region and understand when it is beneficial or necessary to gather insights from stakeholders beyond payers and physicians to answer our client’s questions.

    Questions Our Clients Ask
    • What is the local healthcare environment and payer landscape like in market X?
    • What are the opportunities and challenges in the public and private sectors of market X?
    • What pricing methodology will be employed in Japan? What would be the impact of any cost-effectiveness analysis?
    • What provisions exist for orphan therapies and how can I best access them?
    • What does it take to shift my specialty product from an out of pocket strategy to a reimbursed approach?
    • What are the key learnings from analogs with launch success in this market?
    Local Language Capabilities

    Mandarin, Cantonese, Japanese, Korean & Indonesian

    Specialized Markets

    China, Japan, Korea, Taiwan, Singapore & Indonesia

    The Trinity Difference
    • We partner with clients to design tailored in-depth research methodologies that help to track market dynamics and the most recent pricing and access changes in a country.
    • We are skilled at solving nuanced issues in a fast-paced landscape. We utilize insights from industry experts to provide insightful recommendations.
  • Central and Eastern Europe

    Trinity delivers unique insights for the Central and Eastern Europe region that are locally accurate with deliverable quality that matches that seen for Western Europe and the US.

    Questions Our Clients Ask
    • Which funding routes are available across national, regional, and local channels?
    • How can we provide access and support patients not covered under healthcare budget?
    • How influential are third parties in reimbursement decisions (e.g. KOLs, patient associations
    • What would be an appropriate price point for PRODUCT X for it to be successful in obtaining reimbursement listing?
    • Would PRODUCT X have an advantage if it is manufactured / packaged domestically? What are opportunities for technology transfers to ensure a certain market share?
    Local Language Capabilities

    Russian & Polish

    Specialized Markets

    Russia, Poland, Czech Republic, Hungary, Bulgaria, Greece, Romania, Ukraine, Kazakhstan, Belarus

    The Trinity Difference
    • We have a comprehensive knowledge of local market dynamics for stakeholders within key markets in Eastern Europe and the CIS region.
    • We address nuanced questions on CEE-relates issues coming from regional and global clients on topics such as: IRP dynamics implications, interpretation of policy update and overview of the reimbursement landscape.
  • EUROPE, UK, AND CANADA

    We work with clients to meet the unique local needs of health systems across Europe (EU), UK and Canada while ensuring the integrity of both their regional and commercial access objectives. We have the global expertise to engage with business unit leaders on cross-market strategy, and our in-house local expertise and experience is paired with a strong network of healthcare decision-makers across the region.

    Questions Our Clients Ask
    • What is the pricing, access, and/or commercial opportunity for my asset in the EU?
    • How can we develop a value proposition that meets the needs of customers across markets and roles?
    • Based on our pivotal trial, what HTA outcomes are likely in the EU, and how can we improve this potential? How will positive or negative outcomes in one EU market influence the others?
    • How will follow-on indications impact our pricing and access, and what does this mean for our launch and submission strategy?
    Local Language Capabilities

    German, French, Spanish, Portuguese, Italian & Dutch

    Specialized Markets

    Germany, Great Britain, France, Italy, Spain, Sweden, NetherlandsCanada 

    The Trinity Difference
    • We have active collaborations with thought leaders for conference publications and presentations
    • We run a host of different virtual and face-to-face research that is customized depending on project type and dynamics so that our clients can gain insights firsthand. Methodologies include: online quant and qual surveys, dyads & tryads, internal workshops, webinars, working sessions, mock-negotiation workshops, 1:1 telephone discussions, unblinded ad-boards, and focus groups
    • Our relationships are personal and critical to receive up-to-date and informed perspectives
    • We have experience facilitating logistically complex affiliate strategy and training workshops and meetings with upwards of 100+ cross-functional participants
  • Latin America

    Our LatAm experts have deep regional expertise across therapeutic areas. The most notable project work to date is concerned with oncology, inflammatory diseases, rare diseases, multiple sclerosis and respiratory diseases.

    Questions Our Clients Ask
    • What are the market segments with the highest opportunity at launch, and how do we unlock them?
    • How can we influence local policy to help shape the P&MA landscape?
    • What is the trade-off between price and volume by pursuing specific sub-populations and market segments?
    • How can we prepare our local teams to effectively deliver value stories that resonate with their local stakeholders?
    Local Language Capabilities

    Spanish & Brazilian Portuguese

    Specialized Markets

    Brazil, Argentina, Colombia, Mexico, Panama, Dominican Republic

    The Trinity Difference
    • Our dedicated team of LatAm experts truly understand the complexities or each major market within the region. We strive to ensure our insights are delivered with complete accuracy and by consultants who speak the local languages of our network.
    • We address nuanced questions for local teams and ensure our deliverable quality that matches that seen for Western Europe and the US.

Knowledge Hubs

Cell and Gene Therapy

Cell and Gene Therapy

Cell and gene therapies represent a fundamental therapeutic revolution. Our expert team focuses on assessing the unique opportunities and challenges associated with the emerging class of novel treatments. With a lens towards identifying key value, access and pricing dynamics, we can determine the influence these innovative treatments will have when entering the cell and gene therapy market.

Learn More

Digital Therapeutics and Health Technology

Digital Therapeutics and Health Technology

Digital health technologies are evolving rapidly and are playing an increasingly significant role in both the companion diagnostic and treatment paradigms. Trinity’s experts draw upon their deep understanding of access and reimbursement decision-making for traditional therapeutics to identify and analyze the most impactful events and landscape shifts in the digital space.

Learn More

Latest Evidence, Value, Access and Pricing Intelligence

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. […]

Read now

HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America

HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America

This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC […]

Watch now

France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products

France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products

French president Emmanuel Macron announced a two-year trial that will allow pharmaceutical products that receive an ‘Amélioration du Service Médical Rendu’ (ASMR) rating of IV or better to get reimbursement […]

Read now

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries […]

Read now

Meet our Evidence, Value, Access and Pricing Experts 

Mónica Martín de Bustamante

Mónica Martín de Bustamante

Senior Partner,
Evidence, Value, Access & Pricing

Ms. Martin de Bustamante’s career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the mature and emerging markets, with deep expertise in the USA, EU5, CAN, and JPN. Ms. Martin de Bustamante has worked across the major therapeutic areas (oncology, cardiovascular, neurology, […]

Meet the Team

Robert Albarano

Robert Albarano

Managing Director

Rob is a Managing Director in Trinity’s Evidence, Value, Access, and Pricing practice. Prior to joining Trinity, Rob was a Managing Director (Partner) at L.E.K. Consulting. Rob has 20+ years of healthcare strategy consulting experience, including ~15 years of Market Access and commercial strategy experience. His Market Access experience includes developing launch, pricing, innovative and […]

Meet the Team

Valeria Boers Trilles

Valeria Boers Trilles

Director,
Value, Access & Pricing

Ms. Boers is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Boers was part of the CBPartners team and focused her experience on pricing and market access engagements, proving strategic support to optimize value communication, product positioning, IRP-based launch sequence and pricing opportunity across a range of therapeutic areas, […]

Meet the Team

Christian Frois

Christian Frois

Partner,
Value, Access & Pricing

Christian is a recognized and widely published expert on pricing, contracting, market access and payer evidence strategy. He leads Trinity’s pricing, market access, reimbursement and contracting (PARC) group, and has supported the development of PARC strategies for more than 50 assets in the US and ex-US.

Meet the Team

Andrew Gould

Andrew Gould

Managing Director,
Value, Access & Pricing

Mr. Gould is a Managing Director in Trinity’s Value, Access, and Pricing practice. Prior to joining Trinity, he led CBPartners’ U.S. Center of Excellence and focused on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch and in-line assets within the U.S. Specifically, Mr. Gould […]

Meet the Team

John Greenaway

John Greenaway

Partner,
Value, Access & Pricing

John co-leads our San Francisco office and team and drives growth in our strategic advisory service offering in Pricing, Access, Reimbursement, and Contracting (PARC). Since 1999, John has been leading strategic contracting initiatives, brand planning, forecasting, and product launch strategies to inform customers’ data-driven strategic decision making with market research, quantitative analysis, and financial modeling. […]

Meet the Team

Nandini Hadker

Nandini Hadker

Partner,
Evidence Strategy

An Economist by training, Nandini is a Partner at Trinity Lifesciences with over two decades of experience in the custom research and strategy consulting. She is seasoned at helping clients identify what evidence will be crucial in driving their product’s success, generating that evidence using publication-grade research, and pulling the insights through scientific dissemination. She […]

Meet the Team

Maximilian Hunt

Maximilian Hunt

Partner,
Value, Access & Pricing

Mr. Hunt is a Partner in Trinity’s Value, Access, and Pricing practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases, and cell and gene therapies.  Prior to joining Trinity, Mr. Hunt’s engagement work at CBPartners targeted a variety of commercial business issues related […]

Meet the Team

Miguel Martín de Bustamante

Miguel Martín de Bustamante

Partner,
Value, Access & Pricing

Prior to joining Trinity, Mr. Martín de Bustamante worked across CBPartners’s practices, with a focus on Value, Access, and Pricing. He developed expertise across many related areas, including innovative contracting and access models, strategic product / portfolio positioning, IRP and commercial opportunity based launch sequencing, as well as value positioning across various therapeutic areas. He […]

Meet the Team

Matt O'Hara

Matt O’Hara

Managing Director,
Evidence Strategy

Matt joins Trinity with over 20 years of life sciences consulting experience. During his career, Matt has worked with both pharmaceutical and medical device clients across business/commercial strategy (pricing, market access, product portfolio rationalization, acquisitions, Intellectual Property, and market insights), HEOR (value proposition development, evidence generation planning, and literature reviews, budget impact and comparative effectiveness […]

Meet the Team

Bami Oshinowo

Bami Oshinowo

Partner,
Value, Access & Pricing

Prior to joining Trinity, Ms. Oshinowo led engagement work within the Value, Access and Pricing Practice and drove the Early VAP & CP Centre of Excellence at CBPartners. Her primary expertise is on early-stage pipeline issues related to commercial strategy, including competitive positioning, pricing, market access and trial design optimization. Her geographical expertise includes the USA […]

Meet the Team

Shinkyu Park

Shinkyu Park

Director,
Value, Access & Pricing

Mr. Park is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Mr. Park’s work at CBPartners was primarily focused on pricing, market access, and value demonstration engagements in support of strategic planning with a variety of biopharmaceutical clients. Mr. Park has led many global (including USA, EU, Asia-Pac, and LatAm) […]

Meet the Team

Julia Pikus

Julia Pikus

Principal,
Value, Access & Pricing

Ms. Pikus is a Principal in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Pikus led engagement work within the Value, Access and Pricing Practice and drove the Cell and Gene Therapy Centre of Excellence at CBPartners. In this capacity, Ms. Pikus supported a range of qualitative and quantitative engagements to inform […]

Meet the Team

Jeff Skaar

Jeff Skaar

Managing Director,
Evidence Strategy

Jeff supports pharmaceutical, device, and diagnostic companies in demonstrating and communicating the value of their products.  His work is informed by broader experiences in market access and business and clinical strategy, allowing him to craft health economics and outcomes research solutions that dovetail with overall strategic plans for products across their life cycle stages.  In […]

Meet the Team

Mitali Stevens

Mitali Stevens

Director

Dr. Stevens has over 20 years of combined experience in pharma and med tech industries, with a focus on value evidence generation, reimbursement, and market access. During that time, Dr. Stevens has focused her career on understanding stakeholder needs and developing evidence that integrates health economics, medical affairs, reimbursement, and market access solutions for optimal […]

Meet the Team

If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.